SCHEMBL8524830

SCHEMBL8524830

COC(=O)Cc1cccc(N)c1C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.47
KCNH2 Q12809 1/20 0.47
ALDH1A1 P00352 6/20 0.45
GAA P10253 1/20 0.45
GFER P55789 1/20 0.45
KDM4E B2RXH2 4/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
PIK3CA P42336 1/20 0.43
HSD17B10 Q99714 2/20 0.41
CFTR P13569 1/20 0.41
SLC7A5 Q01650 1/20 0.40
HPGD P15428 3/20 0.40
CFD P00746 1/20 0.40
GLA P06280 1/20 0.40
RCE1 Q9Y256 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28842276 0.84 ALDH1A1 (0.46) ALDH1A1GAAGFERKDM4ETSHR
SCHEMBL644296 0.84 ALDH1A1 (0.49) ALDH1A1GAAGFERKDM4ETSHR
SCHEMBL1907798 0.83 ESR1 (0.45) ESR1KCNH2ALDH1A1GAAKDM4E
SCHEMBL10268521 0.83 ALDH1A1 (0.49) ALDH1A1GAAGFERKDM4ETSHR
SCHEMBL12883622 0.83 ALDH1A1 (0.45) ALDH1A1GAAGFERKDM4ETSHR
SCHEMBL29749375 0.83 ALDH1A1 (0.49) ALDH1A1GAAGFERKDM4ETSHR
SCHEMBL728665 0.82 KDM4E (0.49) ESR1ALDH1A1GAAKDM4EHPGD
Hydrochloric Acid SCHEMBL31720563 0.82 ALDH1A1 (0.47) ALDH1A1GAAGFERKDM4ETSHR
SCHEMBL14420088 0.82 NLRP3 (0.47) ALDH1A1KDM4ETSHRSLC7A5HPGD
Hydrochloric Acid SCHEMBL1772178 0.82 ALDH1A1 (0.47) ALDH1A1GAAGFERKDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed
EP-3305789-A1 NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY Shionogi & Co., Ltd. (JP) 2018-04-11 EP disclosed
US-20120130078-A1 INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME OCHS RAYMOND S (US) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130078-A1 INDAZOLE DERIVATIVES AS ADENOSINE MONOPHOSPHATE DEAMINASE (AMPD) INHIBITORS FOR USE IN DIABETES AND RELATED DISEASES OF METABOLIC SYNDROME AMPD1, AMPD3, AMPD2 ESR1 3653/4885KCNH2 4063/4885ALDH1A1 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.